CD19 and lymphoma: In the study by Trujillo et al., CD19 expression was preserved in all assessable cases of THRLBCL at progression [17]; however, the possibility of CD19 loss contributing to resistance cannot be entirely ruled out, especially given the heterogeneous nature of lymphoma biology.